Recently, Henlius has been announced as the newest member company of the Biosimilars Forum, a coalition that advances biosimilars in United States with the intent of expanding access and availability of biological medicines and improving health care.
"Henlius is committed to working with our industry partners to advance our mission of providing patients around the world with high-quality, affordable, and effective biosimilar medicines," said Ping Cao, CBO of Henlius. "We are so excited to join the Forum at this critical impasse — where access and adoption of these medicines is necessary to lower costs and improve healthcare outcomes for patients.”
"I am excited to welcome Henlius as the latest member of the Biosimilars Forum," said Juliana M. Reed, Executive Director of the Biosimilars Forum. "Our Board of Directors and I look forward to collaborating with the Henlius team as we work to make biosimilars accessible to patients as lower-cost, safe, and effective options."
Henlius is a rapidly growing biopharmaceutical provider that develops, manufactures, and distributes leading biologics in over 50 countries worldwide, serving more than 700,000 patients. To date, Henlius has independently developed and launched four biosimilars, in addition to more than 10 biosimilar candidates under development. Among them, HANQUYOU (trade name: HERCESSI™ in the U.S. and Zercepac® in Europe) is a China-developed mAb biosimilar that has been approved in China, the European Union (EU) and U.S. It is approved in the United States, United Kingdom, Canada, France, Germany, Switzerland, Australia, Finland, Spain, Argentina, Saudi Arabia, and Thailand, and it is reimbursed nationally in countries and regions including China, the UK, France and Germany. Recently, HANQUYOU completed its first shipment to the United States.
In collaboration with leading global biopharmaceutical companies such as Accord, Abbott, Eurofarma, Organon, and KGbio, Henlius has proactively established a global commercial layout for its biosimilar product portfolio. Looking ahead, Henlius will continue to strengthen its collaborations with global partners to accelerate the global launch of more high-quality medicines, benefiting more patients worldwide.
About Biosimilars Forum
The Biosimilars Forum works to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care. The Biosimilars Forum provides evidence-based information to inform and support public policies that encourage awareness, access, and adoption of biosimilars.
The members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios, specifically Amneal Pharmaceuticals, Biocon Biologics, Henlius, Meitheal Pharmaceuticals, Organon, Pfizer Inc., Samsung Bioepis, Sandoz, and Teva Pharmaceuticals.